Nurse-led Proactive Telephone Follow-up With Patients After Completion of Primary Cancer Treatment
Launched by UMEÅ UNIVERSITY · Jan 15, 2024
Trial Information
Current as of July 01, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This clinical trial is looking at whether regular phone calls from nurses can help improve the quality of life for patients who have recently completed treatment for breast, colorectal, or prostate cancer. The study will involve two groups: one group will receive these nurse-led follow-up calls at set times, while the other group will continue with standard care without these extra calls. Researchers will compare the two groups by asking participants to fill out surveys about their feelings and experiences after treatment.
To be eligible for this trial, participants should have been primarily treated for breast, colorectal, or prostate cancer with the goal of curing the disease. However, patients who have not received additional treatment, have cognitive impairments, or have issues with alcohol or substance misuse will not be included. This study is currently recruiting participants aged 65 to 74, and it aims to find out if the extra support from nurses can make a meaningful difference in the lives of these patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Being primarily curatively treated for breast, colorectal-, or prostate cancer
- Exclusion Criteria:
- • no adjuvant treatment
- • no cognitive impairment
- • no known alcohol or other misuse
About Umeå University
Umeå University, a leading research institution in Sweden, is dedicated to advancing healthcare through innovative clinical trials and translational research. With a strong emphasis on interdisciplinary collaboration, the university harnesses cutting-edge technology and expert knowledge across various fields to address critical health challenges. Its commitment to ethical standards and patient safety ensures that all clinical trials conducted under its auspices are designed to generate robust scientific evidence, ultimately contributing to improved health outcomes and informed medical practices. Umeå University strives to foster a dynamic research environment that supports the development of new therapies and enhances the understanding of complex health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Umeå, , Sweden
Patients applied
Trial Officials
Senada Hajdarevic, PhD
Principal Investigator
Umeå University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported